SCHEMBL5146505

SCHEMBL5146505

O=S(=O)(NCC(Cc1ccc(Cl)cc1)c1ccc(Cl)cc1)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.56
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
TP53 P04637 3/20 0.56
GAA P10253 3/20 0.56
LMNA P02545 3/20 0.53
NPSR1 Q6W5P4 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
XBP1 P17861 1/20 0.53
ALDH1A1 P00352 4/20 0.51
GBA1 P04062 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
ATM Q13315 1/20 0.48
EGFR P00533 1/20 0.48
ERBB2 P04626 1/20 0.48
CA1 P00915 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5146619 0.93 CA1 (0.55) MAPTMEN1KMT2ATP53GAA
SCHEMBL5144858 0.88 PGR (0.50) MAPTMEN1KMT2ATP53GAA
SCHEMBL5142978 0.86 CA1 (0.44) MAPTMEN1KMT2ATP53GAA
SCHEMBL5144866 0.83 CNR1 (0.47) MEN1KMT2AALDH1A1CA1CA2
SCHEMBL5145076 0.83 MAPT (0.45) MAPTMEN1KMT2AGAALMNA
SCHEMBL5146860 0.77 PKM (0.43) MAPTMEN1KMT2ATP53GAA
SCHEMBL5508771 0.77 MAPT (0.59) MAPTMEN1KMT2ATP53GAA
SCHEMBL5502574 0.77 MAPT (0.59) MAPTMEN1KMT2ATP53GAA
SCHEMBL4662845 0.76 KEAP1 (0.76) MEN1KMT2ATP53GAALMNA
SCHEMBL9312369 0.76 AR (0.55) SMN1; SMN2TBXAS1ADAMTS5MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663113-A4 SUBSTITUTED SULFONAMIDES MERCK & CO INC (US) 2007-06-13 EP claimed
US-20070105914-A1 Substituted sulfonamides MERCK SHARP & DOHME CORP. 2007-05-10 US claimed
EP-1663113-A2 SUBSTITUTED SULFONAMIDES Merck & Co., Inc. (US) 2006-06-07 EP claimed
WO-2005027837-A2 SUBSTITUTED SULFONAMIDES MERCK & CO., INC. (US) 2005-03-31 WO claimed
US-20070105914-A1 Substituted sulfonamides MERCK SHARP & DOHME CORP. 2007-05-10 US disclosed
US-20070105914-A1 Substituted sulfonamides MERCK SHARP & DOHME CORP. 2007-05-10 US disclosed
US-20070105914-A1 Substituted sulfonamides MERCK SHARP & DOHME CORP. 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105914-A1 Substituted sulfonamides CNR2, CNR1, FAAH MAPT 2166/4885MEN1 396/4885KMT2A 1668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.